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SConclusions: The presence of false lumen thrombus is associated with an increase
in long-term aorta related morbidity and mortality. These ﬁndings may have
implications on risk stratiﬁcation, frequency of surveillance imaging, and future
treatments.
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Background: We developed the Covered Endovascular Reconstruction of Aortic
Bifurcation or CERAB-technique for extensive and/or recurrent aortoiliac occlusive
disease using V12 covered balloon expandable stents (Atrium Maquet Getinge Europe
BV) to rebuild the aortic bifurcation.
Methods: Endovascular bifemoral recanalisation of the aortoiliac axes,; placement
and expansion of a 12 mm V12 Large Diameter in the distal aorta (9 Fr). Pick up of
the already expanded V12 stent with an large balloon (adapted to the aortic diameter).
The balloon is so positioned that the distal marker is about 15 mm proximal to the
distal stent margin. After positioning and expansion, the distal stent part becomes
funnel-shaped. Two iliac covered stent-grafts are then placed in this segment, in
a "kissing-stent" conﬁguration and inﬂated. Both stents are now making a very tight
combination with the aortic stent, as were they moulded together, simulating a new
bifurcation
Results: Two-centre prospective, non-randomised, follow-up study. We treated now
70 patients with acute, chronic or recurrent aortoiliac occlusive disease. Technical
success rate up till now was almost 95%. Follow-up 52 – 1 months. 5 patients died of
non-interventional causes . Five patients re-occluded, mainly due to progressive distal
peripheral disease. They received successfully thrombolysis and treatment of the
outﬂow problems. The other patients showed no complications.
Conclusions: Covered Endovascular Reconstruction of Aortic Bifurcation or
CERAB is safe and feasible and can be performed completely percutaneous. A
larger population, longer follow-up, further haemodynamic investigation is needed
Distal peripheral outﬂow needs to be sufﬁcient enough. It can be combined as
a "hybrid" procedure. CERAB can be used for the treatment of recurrent or in-stent
disease It is even feasible to treat lesion that extend to the iuxta and/or supral renal
aortic region
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Background: Revascularization is the optimal treatment to avoid major amputation
for critical limb ischemia (CLI) patients. Although previous studies report that statin
administration is associated with a reduced risk for cardiovascular events, the efﬁcacy
for CLI patients is unclear. In this study, we aimed to compare the outcomes in CLI
patients with statin administration and without statin administration after endovascular
therapy (EVT).
Methods: This study is a subanalysis from Endovascular Treatment for Infra-inguinal
Vessel, in patients with critical limb ischemia, - A Prospective, Multi-center, 12 month
follow-up Registry in Japan: Olive Registry. From November 2009 to December
2011, a total of 310 patients with CLI who underwent EVT for infrainguinal artery
disease were enrolled. The outcome measures were limb salvage and major adverse
limb event (MALE). MALE was deﬁned as major amputation or major reintervention
including surgical procedure.
Results: The mean follow-up period was 294  138 days. Sixty-ﬁve percent were
male, 26% had statin administration. Rutherford class IV was found in 38 patients, V
in 217 patients and VI in 55 patients. Kaplan-Meier survival curve showed that the
limb salvage rate at one year was 97.3% in the statin group, 89.7% in the without
statin group (P¼0.03). In adjusted model, limb salvage rate and freedom from MALE
were statistically higher in the statin group (P<0.01).
Conclusions: Statin administration after infrainguinal angioplasty for CLI patients
improved limb salvage rate and freedom from MALE.B164 JACC Vol 62/18/Suppl B j October 27–NTCT-545
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extensive distal femoropopliteal occlusive disease.
Peter Goverde1, Katrien Lauwers2, Sven Vercauteren2
1ZNA Stuivenberg Hospital, Antwerp, Belgium, 2Vascular Clinic ZNA, Antwerp,
Belgium
Background: In the endovascular treatment of extensive disease in the distal super-
ﬁcial femoral and popliteal level, you can encounter ﬂow limiting problems, where
stent placement is needed after balloon angioplasty. At the moment most of the
standard bare nitinol stents will have difﬁculties in these areas. With the introduction
of the Supera stent (IDEV Technologies, Inc., Texas, US) we may have an answer in
treating those problematic lesions
Methods: Because of the Superas new design; with 6 interwoven nitinol wires, it has
extraordinary characteristics : very ﬂexible, kink, fracture and crush resistant together
with great radial force. We have treated more than 100 patients with extensive distal
femoropopliteal disease (TASC II C & D) with heavy calciﬁcations, occlusions,
recurrent disease, stent fractures etc. These lesions, that not responded to balloon
angioplasty and that needed stent placement, were al treated with placement of Supera
stents.
Results: Results of the single centre prospective AURORAA registry : Follow up
done by ultrasound. Five patients died of non-interventional causes.. Six months
primary patency was more then 90%. Twelve months primary patency was around
81%. We observed further more no stent fractures or ﬂow limiting kinking in this very
difﬁcult "to stent" area (distal superﬁcial femoral artery & popliteal artery). Average
lesion length: 14 cm; average stent length : 18 cm. Technical success rate :96 %
Conclusions: The Supera stent can be a solution when the use of a "classic" nitinol
stent is not indicated or favourable , especially in the femoropoliteal area. It has very
good patency rates, despite the very difﬁcult region to treat This self expandable stent
system can be a necessary complement in your tool box due to its special
characteristics
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Background: The elderly have a high prevalence of peripheral arterial disease (PAD)
and it seems that they may be less suitable for a one day discharge after endovascular
revascularization (ER) mainly due to a higher ratio in hemorrhage complications.
Therefore we sought to evaluate whether the advantages of one day discharge after ER
on lower extremities can be safely extended for the elderly.
Methods: Between January 2008 and June 2012, 455 ER were performed on lower
extremities with Bivalirudin as an anticoagulant. The decision of deployment the
vascular closure device (VCD) was left to the operator discretion. Patients 70 years old
and older were included to the study group (n¼235). The rest of the patients created
the control group (n¼220). The follow up was done at 24 hours and 30 days afterovember 1, 2013 j TCT Abstracts/POSTER/Endovascular Intervention
